Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Galapagos (GLPG)
NASDAQ:GLPG
Earnings Data
Report Date
Apr 23, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.14Last Year’s EPS
0.39Same Quarter Last Year
Moderate Sell
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 12, 2025
|% Change Since: 7.09%
|Next Earnings Date:Apr 23, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in cell therapy and strategic initiatives, such as the separation into two entities and key partnerships. However, challenges in manufacturing setup, deprioritization of certain programs, and workforce reductions were noted. The overall sentiment balances between positive strategic steps and the challenges faced.Company Guidance
During the Galapagos Full Year 2024 Financial Results and Business Update Conference Call, the company provided comprehensive guidance on their strategic direction and financial outlook. Galapagos reported total revenues of €276 million for the year, with research and development expenses at €335 million, marking a 39% increase due to expansion in oncology CAR-T. The company ended the year with approximately €3.3 billion in cash and a cash burn of €293 million, excluding business development. Key strategic initiatives include advancing their flagship CD19 CAR-T program, GLPG5101, with plans to start pivotal studies in 2026 and aim for first approval by 2028. To streamline operations, Galapagos announced the separation into two publicly-traded entities: Galapagos, focusing on cell therapy in oncology, and SpinCo, targeting innovative medicines through partnerships. Galapagos will capitalize on a decentralized manufacturing platform, projecting a cash runway to 2028 with an annual burn rate between €175 million and €225 million. Meanwhile, SpinCo will be capitalized with approximately €2.45 billion to pursue high-quality biotech assets.Advancement of GLPG5101 CD19 CAR-T Program
Galapagos made significant progress in advancing their flagship GLPG5101 CD19 CAR-T clinical development program, receiving FDA's IND clearance to begin clinical studies in the U.S. The program showed promising results in the ATALANTA study, with high overall and complete response rates in refractory/relapsed lymphomas.
Strategic Partnerships and Collaborations
Galapagos executed key partnerships with companies like Lonza, Thermo Fisher, and Adaptimmune to support their cell therapy goals. These partnerships aim to enhance their decentralized manufacturing platform and expand therapeutic applications.
Separation into Two Entities
Galapagos announced plans to separate into two publicly-traded entities, Galapagos and SpinCo. SpinCo will focus on building a pipeline of innovative medicines through transformational transactions, while Galapagos will concentrate on accelerating global oncology leadership.
Financial Performance and Cash Position
Galapagos reported a net profit of €74 million for 2024, driven by fair value adjustments, currency exchange, and interest income. The company ended the year with approximately €3.3 billion in cash.
---
GLPG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GLPG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 12, 2025 | $24.97 | $25.49 | +2.08% |
| Oct 30, 2024 | $28.59 | $26.44 | -7.52% |
| Aug 01, 2024 | $26.89 | $25.52 | -5.09% |
| May 02, 2024 | $29.45 | $29.09 | -1.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Galapagos (GLPG) report earnings?
Galapagos (GLPG) is schdueled to report earning on Apr 23, 2025, TBA Not Confirmed.
What is Galapagos (GLPG) earnings time?
Galapagos (GLPG) earnings time is at Apr 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GLPG EPS forecast?
GLPG EPS forecast for the fiscal quarter 2025 (Q1) is -0.14.
---